Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo

Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo

Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are engaged in a battle of sorts. The two won FDA approval for new non-small cell lung cancer therapies in 2015 that work similarly, and ever since, they've been elbowing at one another for market share. So far, Bristol-Myers Squibb's drug, Opdivo, generates the most in sales, but in the second quarter, sales of Merck's Keytruda closed the gap.

Non-small lung cancer is common, and unfortunately, despite improving survival statistics, it's still a major cause of death.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com